WVE 210201

Drug Profile

WVE 210201

Alternative Names: Exon 51 modulators - Wave Life Sciences; WVE-210201

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator WaVe life Sciences
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Duchenne muscular dystrophy

Most Recent Events

  • 06 Nov 2017 Phase-I clinical trials in Duchenne muscular dystrophy in USA (IV)
  • 06 Nov 2017 Preclinical trials in Duchenne muscular dystrophy in USA (SC)
  • 06 Nov 2017 Wave Life Science plans an efficacy multi-dose trial for Duchenne muscular dystrophy in USA in second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top